The clinical nutrition industry is shifting from supportive care to front-line therapy, as hospitals increasingly recognize its role in reducing complications, hospital stays, and mortality. With global market size rising from USD 52.6 billion in 2023 to USD 78.4 billion by 2030, at a CAGR of 5.9%, the focus has moved to precision nutrition in critical care, oncology, and aging populations. Nearly 60–65% of ICU patients now receive some form of tailored enteral or parenteral nutrition, contributing to improved outcomes and cost savings.
Driven by the dual burden of malnutrition and non-communicable diseases, Asia-Pacific is seeing record adoption rates growing at 7.2% CAGR, with government-funded programs expanding in India, Indonesia, and China. Meanwhile, North America continues to dominate with over 35% global market share, largely due to reimbursement coverage and high rates of chronic illness. Clinically fortified nutrition rich in whey protein, glutamine, arginine, and omega-3s has been proven to reduce post-surgical infection rates by 20–25%, and accelerate wound healing by up to 28%.
Download the full transcript for deep dives into reimbursement shifts, disease-linked demand, and how next-gen formulas are reshaping recovery science.